Faculty: Kevin Alexander, MD

This brief clinical discussion examines findings presented at the ESC Heart Failure 2025 meeting in Belgrade, Serbia, on the impact of acoramidis in transthyretin amyloid cardiomyopathy (ATTR-CM). The analysis highlights a reduction in atrial fibrillation events and an improvement in cardiovascular outcomes among patients treated with acoramidis, including those with both wild-type and variant transthyretin (TTR). Data from the ATTRibute-CM study are reviewed, showing associations between treatment and increased serum TTR levels, delayed time to first cardiovascular hospitalization, reduced NT-proBNP levels, and lower all-cause mortality. These results suggest a clinically meaningful benefit of acoramidis and support its potential role in managing ATTR-CM.

Faculty: Ahmad Masri, MD, MS

Review findings from the UK Biobank presented recently at the Peripheral Nerve Society meeting, revealing that naturally low transthyretin (TTR) levels are associated with a higher prevalence of cardiovascular biomarkers, such as NT-proBNP, and comorbidities, including peripheral arterial disease, stroke, and cognitive decline. The data suggest that low TTR may serve as a marker of broader systemic illness, both in patients with TTR amyloidosis and in the general population.

Guest: Muthiah Vaduganathan, MD, MPH

Guest: Anuradha Lala-Trindade, MD

Guest: Brendon Neuen, MBBS, PhD

Heart failure with mildly reduced ejection fraction (HFmrEF) and preserved ejection fraction (HFpEF) represent a significant and growing burden for patients and the healthcare system, not only in cardiovascular medicine, but also in the context of cardio-kidney-metabolic (CKM) syndrome. Trials are underway evaluating new therapies that may offer benefits to patients with HFmrEF/HFpEF and may also have broader, multisystem effects. Tune in to stay up to date!

Host: Alejandro A. Rabinstein, MD, FAHA

Guest: Richard E. Pratley, MD

Guest: Jay H. Shubrook, DO, FACOFP, FAAFP

Listen to expert faculty discuss the role of GLP-1RAs in reducing stroke risk for patients with type 2 diabetes in this on-demand webcast with accompanying slides

Host: Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC

Guest: Rishi Wadhera, MD, MPP, Mphil

Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.

Host: Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC

Guest: Rishi Wadhera, MD, MPP, Mphil

Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.

Host: Rishi Wadhera, MD, MPP, Mphil

Guest: Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC

Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.

Host: Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC

Guest: Rishi Wadhera, MD, MPP, Mphil

Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.

Host: Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC

Guest: Rishi Wadhera, MD, MPP, Mphil

Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.

Host: Riccardo Maria Inciardi, MD, PhD

Listen to Dr. Riccardo Inciardi’s summary from the ESC Preventive Cardiology 2025 meeting, where he highlights new therapies reshaping the management of cardio-kidney-metabolic (CKM) syndrome and heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). Watch as he breaks down the latest clinical trial data showing that SGLT2 inhibitors, GLP-1 receptor agonists, and the nonsteroidal MRA finerenone can meaningfully reduce hospitalizations, kidney disease progression, and cardiovascular mortality. A real-life patient case illustrates how combining these therapies—under the care of a multidisciplinary team—can transform outcomes.